通过动力学分析对阿皮卡对帕金森病的影响进行客观评估
Matteo Bologna1,2, Andrea Guerra3,4, Donato Colella5
1Department of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185, Rome, Italy. matteo.bologna@uniroma1.it.
概括
奥皮卡 (OPC) 显著改善了帕金森病 (PD) 患者的手指运动布拉迪基尼西亚,当添加到L-DOPA治疗时. 这种客观的动力学分析显示,运动变异性减少,振幅增加,特别是在OFF期间.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物机械工程 生物机械工程
背景情况:
- 帕金森病 (PD) 的特点是运动波动.
- 奥皮卡 (OPC) 是一种选择性的外围COMT抑制剂,增强了L-DOPA的疗效.
- OPC减少了PD患者的OFF时间和运动波动.
研究的目的:
- 客观地评估添加Opicapone (OPC) 添加L-DOPA对PD患者勃拉迪基尼西亚的影响.
- 利用手指运动的动力学分析进行客观的运动评估.
- 评估L-DOPA管理后不同时间点的运动功能的变化.
主要方法:
- 20名PD患者参与了运动波动.
- 对重复的手指运动进行了动力学分析.
- 患者接受了两次会议:单独的L-DOPA和L-DOPA + OPC,在四个时间点进行测量.
主要成果:
- 与单独使用L-DOPA相比,使用L-DOPA + OPC的手指运动速度和幅度显著更高.
- 在L-DOPA + OPC疗程中,运动变异性明显较低.
- 在所有测试时间点中都观察到改善.
结论:
- 这是首次对患有运动波动的PD患者对奥皮卡 (OPC) 的客观动力学评估.
- 将OPC添加到L-DOPA治疗中显著改善了勃拉迪基尼西亚.
- 在临床上相关的时期,包括OFF,延迟启动和磨损关闭状态,OPC可以增强运动功能.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.9K
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.8K
相关概念视频
01:24Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
01:15Parkinson's Disease: Overview
556
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
556